Iranian Journal of Pathology

Plasmapheresis- Review Article

Document Type : Review Article

Author

Alireza Abdollahi

1. Dept. of Pathology, Tehran University of Medical Sciences, Tehran, Iran 2. Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract
Plasmapheresis, which is defined as the removal of plasma, can be either "adjusted plasma" or “exchange of plasma”. The former is defined as selective withdrawal of certain (un)-pathological plasma components in different ways such as perfusion and then returning the remained donor plasma to him, the latter is non-selective removal of all components of plasma to provide blood products for injection into patients or to be used as the input of blood transfusion refinery or to remove the pathogen contained plasma before compensating for the volume losses with an equal volume of plasma or more commonly, replacing plasma with a substitute fluid (colloid or crystalloid) such as albumin. Plasmapheresis was divided generally into two groups:
1-      Plasma products by donor plasmapheresis
2-      Therapeutic plasmapheresis
Therapeutic plasma exchange or TPE are often attributed to plasma that exit from the body of patient then compensated by any kind of replacement fluid volumes to support neurmolemic situation of patients. Plasmapheresis is currently used as a therapeutic modality in a wide array of conditions. Generally, plasmapheresis is used when a substance in the plasma, such as immunoglobulin, is acutely toxic and can be efficiently removed. Myriad conditions fall under this category, including neurologic, hematologic, metabolic, dermatologic, rheumatologic, and renal diseases, as well as intoxications, that can be treated with plasmapheresis.

Keywords

Plasmapheresis
Exchange the Plasma
  1. Crookston KP, Richter DM. Teaching and learning apheresis medicine: The Bermuda Triangle in Education. J Clin Apher 2010; 25(6):338-46.
  2. Witt V. Training courses for pediatric apheresis on site; how apheresis technology transfer can be performed. Transfus Apher Sci 2010; 43(2):223-5.
  3. Gahar LR, Visser O. The ins and outs of hemapheresis units in the Netherlands: practice and organization. Transfus Apher Sci 2013; 48(2):201.
  4. Sadeghi M, Daniel V, Wang H, Zeier M, Schemmer P, Mehrabi A,et al. Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients. Transplantation 2013; 95(8):1021-9.
  5. Makroo RN, Walia RS, Aneja S, Bhatia A, Chowdhry M. Preoperative predictors of bloo component transfusion in living donor liver transplantation. Asian J Transfus Sci 2013; 7(2):140-6.
  6. Hunt EA, Jain NG, Somers MJ. Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease. J Clin Apher 2013; 28(1):36-47.
  7. Federici AB, Vanelli C, Arrigoni L. Transfusion issues in cancer patients. Thromb Res 2012; 129 Suppl 1:S60-5.
  8. Brand A. Passenger leukocytes, cytokines, and transfusion reactions (editorial). N Eng J Med 1994; 331: 670-1.
  9. Smith Jw, Gilcher RO. Red blood cells, plasma, & other new apheresis drived blood products: Improving product quality & donor utilization. Transfus Med Rev 1999; 13: 118-23.
  10. Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for TTP. J Clin Apheresis 1995; 10: 178-82.
  11. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998; 38(10):938-43.
  12. Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol 2011; 5; 7(9):499-508.
  13. Oslon PR, Cox C, McCoullough J. Laboratory and clinical effects of the infusion of ACD solution during plateletpheresis. Vox Sanguinis 1987; 33: 79-87.
  14. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apheresis 1994; 9: 130-4.
  15. Powel L. Intense plasmapheresis in the pregnant Rh sensitized woman. Am J Obstet Gynecol 1968; 101(2):153-70.
  16. Isojima S, Hisano M, Suzuki T, Sago H, Murashima A, Yamaguchi K. Early plasmapheresis followed by high-dose γ-globulin treatment saved a severely Rho-incompatible pregnancy. J Clin Apher 2011;26(4):216-8.
  17. Clarke CA, Elson CJ, Bradley J, Donohoe WT, Lehane D, Hughes-Jones NC. Intensive plasmapheresis as a therapeutic measure in Rhesus-immunized woman. Lancet 1970 18;1(7651):793-8.
  18. Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood Purif 2012;33(1-3):190-8.
  19. Jones JV, Cumming RH, Bacon PA, Evers J, Fraser ID, Bothamley J, et al.Evidence for a therapeutic effect of plasmapheresis in patient with systemic lupus erythematosus. Q J Med 1979; 48(192):555-76.
  20. Nollet KE. Blood banking and transfusion medicine in extreme or resource-limited conditions. Transfus Apher Sci 2013 Sep 14. doi:pii: S1473-0502(13)00285-1. 10.1016/j.transci.2013.09.002.
  21. Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003; 82(1):27-38.
  22. Ibrahim RB, Balogun RA. Medications and therapeutic apheresis procedures: are we doing our best? J Clin Apher 2013; 28(1):73-7.
  23. Williams ME. Starting a new therapeutic apheresis service: medical directorship and other matters. J Clin Apher 2013; 28(1):11-5.
  24. Kawasaki Y, Ono A, Ohara S, Suzuki Y, Suyama K, Suzuki J, et al. Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci 2013; 59(1):15-26.
  25. Dau PC. Immunologic rebound. J Clin Apher 1995; 10(4):210-7.
  26. Rummler S, Maier K, Barz D. Therapeutic apheresis in transplantation medicine, experience with cardiac and lung transplantation in Jena. Atheroscler Suppl 2013;14(1):33-8.
  27. Dyer M, Neal MD, Rollins-Raval MA, Raval JS. Simultaneous extracorporeal membrane oxygenation and therapeutic plasma exchange procedures are tolerable in both pediatric and adult patients.Transfusion 2013; 10.
  28. Orlin JB, Berkman EM. Partial plasma exchange using albumin replacement: Removal & recovery of normal plasma constitutes. Blood 1980; 56: 1055-9.
  29. Mcleod Bc, Sassetti RJ, Stefoski D, Davis FA. Partial plasma protein replacement in therapeutic plasma exchange. J Clin Apher 1983;1(2):115-8.
  30. Waldmann TA, Strober W. Metabolism of Immunoglobulins. Prog Allergy 1969;13:1-110.
  31. Michaud M, Pourrat J. Cryofibrinogenemia. J Clin Rheumatol 2013; 19(3):142-8.
  32. Wells JV, Fundenberg HH. Metabolism of radio-iodinated IgG in patients with abnormal serum IgG levels. Hypergammaglobulinemia. Clin Exp Immunol 1971;9(6):775-83.
  33. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML,et al.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28(3):145-284.
  34. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008; 14(13):1261-9.
  35. Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci 2013; 7(1):37-41.
  36. Dau PC. Immunologic rebound. J Clin Apheresis.1995; 10: 210-7.
  37.  Derksen RH, Schuurman HJ, Meyling FH, Struyvenberg A, Kater L, et al. The efficacy of plasma exchange in the removal of plasma components. J Lab Clin Med. 1984; 104(3):346-54.
  38. Junghans RP. IgG biosynthesis. No " Immunoregulatory feedback ". Blood 1997; 90: 3815-8.
  39. Yu Z, Lennon VA. Mechanism of intravenous immunoglobulin therapy in antibody-mediated autoimmune disease. N Eng J Med 1999; 340: 227-8.
  40. Poisson JL, Low A, Park YA. The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange. J Clin Apher 2013; 28(4):317-20.
  41. Cortese I, Cornblath DR. Therapeutic plasma exchange in neurology: 2012. J Clin Apher 2013; 28(1):16-9.
  42. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326(21):1373-9.
  43. Loo CY, Mohamed Said MS, Mohd R, Abdul Gafor AH, Saidin R, Halim NA. Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci 2010; 43(3):335-40.
  44. Pool M, Mcleod BC. Pyrogen reactions to human serum albumin during plasma exchange. J Clin Apher 1995; 10(2):81-4.
  45. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013; 14(1):19-27.
  46. Winters JL. Apheresis in the treatment of idiopathic dilated cardiomyopathy. J Clin Apher 2012; 27(6):312-9.
  47.  McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ ,et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1999; 39: 282-8.
  48. Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for TTP. J Clin Apheresis 1995; 10: 178-82.
  49. Weinstein R. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apheresis 1996; 11: 204-10.
  50. Pierce LR, Gaines A, Finlayson JS, Varricchio F, Epstein JS. Hemolysis & acute renal failure due to the administrations of albumin diluted in sterile water [letter]. Transfusion 1999; 39: 110-1.
  51. Hattersley JG, Chappell MJ, Zehnder D, Higgins RM, Evans ND. Describing the effectiveness of immunosuppression drugs and apheresis in the treatment of transplant patients. Comput Methods Programs Biomed 2013; 109(2):126-33.
  52. Stigelman WH, Henry DH, Talbert RL, Townsend RJ. Remove of prednisone & prednisolone by plasma exchange. Clin Pharmacy 1984;3: 402-7.
  53. Ibrahim RB, Liu CY, Cronin SM, Murphy BC, Cha R, Swerdlow P, et al. Influence of plasma exchange on the disposition of the fourth generation cephalosporin cefepime. J Oncol Pharm Pract 2009; 15(4):217-22.
  54. Wood GJ, Hall GM. Plasmapheresis and plasma cholinesterase. Br J Anaesth 1978; 50(9):945-9.
  55. Perseghin P, Capra M, Baldini V, Sciorelli G. Bradykinin production during donor plasmapheresis procedures. Vox Sang 2001; 81(1):24-8.
  56. Owen HG, Brecher ME. Partial colloid replacement for therapeutic plasma exchange. J Clin Apheresis 1997; 12: 87-92.
  57.  Sultan Y, Bussel A, Maisonneuve P, Poupeney M, Sitty X, Gajdos P. Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease. Transfusion 1979; 19: 558-93.
  58. Domen RE, Kennedy MS, Jones LL, Senhauser DA. Hemostatic imbalances produced by plasma exchange. Transfusion 1984; 24: 336-8.
  59. Flaum MA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK, Gralnick HR. The hemostatic imbalance of plasma exchange transfusion. Blood 1979;54(3):694-702.
  60. Karussis D. Immunotherapy of multiple sclerosis: the state of the art. BioDrugs. 2013; 27(2):113-48.
  61. Kamel H, Tomasulo P, Bravo M, Wiltbank T, Cusick R, James RC, et al. Delayed adverse reactions to blood donation. Transfusion 2010; 50(3):556-65.
  62. Salam A, Hosain GM, Narvios A, Sazama K, Lichtiger B. Immediate adverse reactions to platelet transfusions: whole blood derived versus apheresis platelets. Mymensingh Med J 2013; 22(1):143-7.
  63. McClellan SD, Whitaker CH, Friedberg RC. Removal of vancomycin during plasmapheresis. Ann Pharmacother 1997; 31(10):1132-6.
  64. Strauss RG. Mechanisms of adverse effects during hemaheresis. J Clin Apher 1996; 11(3):160-4.
  65. Silberstein LE, Naryshkin S, Haddad JJ, Strauss Jf. Calcium hemostasis during therapeutic plasma exchange. Transfusion 1986; 26(2):151-5.
  66. Crookston KP, Simon TL. Physiology of apheresis. In: Mcleod BC, Price MJ, et al. Aheresis: principles & practice.2th ed.Bethesda., MD: AABB press. 2003,
  67. Szymanski IO. Ionized calcium during plateletpheresis. Transfusion 1978; 18(6):701-8.
  68. Karagiorgou LZ, Pantazopoulou MN, Mainas NC, Beloukas AI, Kriebardis AG. Knowledge about umbilical cord blood banking among Greek citizens. Blood Transfus 2013 ; 3:1-7.
  69. Hester JP, Ayyar R. Anticoagulant & electrolytes. J Clin Apheresis 1984; 2: 41-51.
  70. Bolan CD, Cecco SA, Wesley RA, Horne M, Yau YY, Remaley AT, et al.Controlled study of citrate effects and response to IV calcium administration during allogenic peripheral blood progenitor cell donation. Transfusion 2002; 42: 935-46.
  71. Korach JM, Berger P, Giraud C. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med 1998; 24: 452-8.
  72. Dutcher JP, Aisner J, Hogge DE, Schiffer CA. Donor reaction to hydroxyethyl starch during granulocytapheresis. Transfusion 1984; 24(1):66-7.
  73. Ring J, Messmer K. Incidence & severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977 26; 1(8009):466-9.
  74. Kannan S, Milligan KR. Moderately sever anaphylactoid reaction to pentastarch(200/0.5) in a patient with acute severe asthma. Intensive Care Med 1999; 25(2):220-2.
  75. Martínez Álvarez JC. Antibodies, human leukocyte antigens, and biomodulators in transfusion-related acute adverse effects. Gac Med Mex 2013; 149(1):81-8.
  76. Nollet KE, Ohto H, Yasuda H, Hasegawa A. The great East Japan earthquake of March 11, 2011, from the vantage point of blood banking and transfusion medicine. Transfus Med Rev 2013; 27(1):29-35.
  77. Leitman SF, Boltansky H, Alter HJ, Pearson FC, Kaliner MA. Allergic reactions in healthy plateletpheresis donor caused by sensitization to ethylene oxide gas. N Eng J Med1986; 315: 1192-6.
  78. Owen HG, Brecher ME. Atypical reactions associated with use of ACEI & apheresis. Transfusion 1994; 34(10):891-4.
  79. Aghishi T. Anion-blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors. JAMA 1994; 271(3):195-6.
  80. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulfate & ACE inhibitors. Lancet 1993; 341: 60-1.
  81. Jaime-Perez JC, Monreal-Robles R, Colunga-Pedraza J, Mancías-Guerra C, Rodríguez-Romo L, Gómez-Almaguer D. Cord blood banking activities at a university hospital in northeast Mexico: an 8-year experience. Transfusion 2012; 52(12):2606-13.
  82. Newman BH. Donor reactions & injuries from whole blood donation. Transfus Med Rev 1997; 11(1):64-75.
  83. Montacer-kuhsari J, Voller H, Keller F. Pulmonary air embolism. Intensive Care Med 1994;20(2):166-7.
Iranian Journal of Pathology
Volume 9, Issue 3 - Serial Number 3
Summer 2014
Pages 167-180

  • Receive Date 26 July 2013
  • Revise Date 26 February 2014
  • Accept Date 26 April 2014

Home

Guide for Authors

Submit Manuscript

Contact Us